Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "GE"

9922 News Found

Kokilaben hospital performs first remote robotic kidney surgery
Hospitals | April 09, 2026

Kokilaben hospital performs first remote robotic kidney surgery

Surgeon Yuvaraja operates on a 55-year-old patient at Medical City Hospital Muscat


Leeford scales science-led skincare bet with Alite as acne-care demand surges
Healthcare | April 09, 2026

Leeford scales science-led skincare bet with Alite as acne-care demand surges

Drugmaker taps 1 million retail touchpoints, quick commerce and modern trade to expand ingredient-led skincare franchise


Dr. Jitendra Singh urges industry to step up R&D collaboration
R&D | April 09, 2026

Dr. Jitendra Singh urges industry to step up R&D collaboration

Minister highlights RDI fund, private participation in space and nuclear sectors, and calls for faster reforms to improve ease of research in India


India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters
Drug Approval | April 09, 2026

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga


Transgene and NEC join forces to advance personalized cancer vaccine
R&D | April 08, 2026

Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor


Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health
News | April 08, 2026

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners


Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity
Drug Approval | April 08, 2026

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size


Asia emerges new hotspot for healthcare ransomware, says report
Digitisation | April 08, 2026

Asia emerges new hotspot for healthcare ransomware, says report

Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs